Aviado · Research
Longevity Daily
Thursday, July 23, 2026
Listen
Today's Brief
The FDA's advisory review of therapeutic peptides — meeting this week to decide whether to ease access restrictions — is the longevity community's most consequential policy moment in years, and it headlines today's issue. Two studies take a wrecking ball to the core NAD+ premise, while USC researchers identify the first thymus-derived hormone shown to reverse age-related inflammation. Midlife brain genomics and a 70%-effective AGE-clearing enzyme round out a strong research day. Bryan Johnson's stem-cell clone announcement, covered here with appropriate skepticism, keeps the boundary between biohacking and science deliberately blurry.
10 stories5 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Your Brain's Genome Starts Rewiring Itself in Midlife — Long Before Symptoms Appear
A new study reveals that the human hippocampus undergoes sweeping changes in 3D genome architecture and gene regulation beginning in midlife — long before any cognitive symptoms emerge. This is not ordinary cellular wear and tear; it is a coordinated biological shift that may set the stage for memory decline decades later. If these genomic changes can be detected or slowed, midlife may be the critical intervention window for protecting long-term brain health.
Read more →Blood Test for p-Tau217 Predicts Alzheimer's Risk Years Before Any Symptoms
Presented at AAIC 2026, new findings show that elevated phosphorylated tau 217 in a routine blood draw predicts cognitive decline years before noticeable memory problems — even in adults who appear neurologically healthy. The marker was associated with faster decline on a validated Alzheimer's cognitive composite scale. Lead researcher Buckley noted: 'Our findings provide some of the clearest evidence yet that elevated p-tau217 levels may help detect dementia risk years earlier' — a meaningful step toward catching the disease when interventions are most likely to work.
Read more →Supplements & Compounds
NAD+ Levels May Not Decline With Age in Healthy People — Challenging a Core Supplement Premise
The foundational selling point behind NAD+ supplementation — that levels inevitably drop as you age — may not hold in healthy individuals. Two studies from earlier this year, including one not yet peer-reviewed, found no significant age-related decline in NAD+ among people without metabolic disease. This does not rule out benefits for those with compromised mitochondrial function, but it raises pointed questions about whether healthy adults are spending money solving a problem they do not have.
Read more →Research & Papers
USC Scientists Identify Thymus Hormone That Reverses Age-Related Inflammation
Researchers at USC's Keck School of Medicine have identified thymulin — a hormone produced by the thymus gland — as the first naturally occurring substance shown to both decline with age and actively reverse inflammaging when restored. Past work linked the thymus to chronic inflammation, but this is the first study to pinpoint the specific biological mechanism. The finding opens a potentially new therapeutic pathway for treating systemic inflammation without the side effects of immunosuppressive drugs.
Read more →Engineered Enzyme Erases a Key Aging Biomarker by Up to 70% in Human Tissue Samples
Scientists have developed CMLase, an engineered enzyme capable of breaking down CML, a type of advanced glycation endproduct that accumulates in tissues with age and drives inflammation and stiffness. In human tissue samples, the enzyme reduced CML levels by up to 70% — a significant proof-of-concept for clearing metabolic debris that no current intervention can meaningfully address. This is still early-stage research, but AGE-breaking enzymes represent one of the more credible frontiers in anti-aging biomedicine.
Read more →Aviado Research Review: Longevity Science Findings Worth Your Attention
Our in-house research team reviews emerging findings across longevity science, translating primary literature into actionable insights for health-optimizing readers. This edition examines recent developments in aging biology and their implications for supplementation and lifestyle decisions.
Read the full Aviado analysis →Lifestyle & Nutrition
21-Year Study: Lifestyle Changes Outperform Metformin for Long-Term Chronic Disease Prevention
In one of the longest-running prediabetes intervention trials, lifestyle modification — not metformin — was the only strategy associated with a significantly lower burden of multimorbidity over 21 years of follow-up. Adults who adopted structured diet and exercise programs had measurably lower rates of developing multiple chronic conditions compared to both metformin users and controls. For longevity-minded readers, the message is blunt: no drug yet replicates the compound protective effect of sustained lifestyle change.
Read more →Gut Jet Lag Is Real — And It Lingers Long After You Have Landed
A new study introduced the concept of gut jet lag — the desynchronization between your biological clock and gut microbiota rhythms that occurs during long-haul travel. This disruption is distinct from brain-based jet lag and impairs digestion, immunity, and metabolic regulation for days after landing. For frequent travelers, timed eating aligned to the destination time zone may offer more targeted microbiome recovery than melatonin alone.
Read more →Industry & Policy
The FDA Is Deciding the Future of Peptides This Week. Here's What You Need to Know
A little-known FDA advisory committee met this week to determine whether popular therapeutic peptides — widely used for muscle recovery, inflammation reduction, and longevity — should be legalized beyond their current research-only status. If restrictions ease, a booming gray market would move into regulated territory, making these compounds more accessible and safer for the millions sourcing them without oversight. The stakes extend well beyond BPC-157 and TB-500: this ruling will set a precedent for how the FDA treats the broader category of performance and longevity biologics. This is the most consequential regulatory moment for the longevity supplement space in years.
Read more →Bryan Johnson Claims He Cloned Himself as a Newborn to Grow Replacement Organs
Longevity entrepreneur Bryan Johnson announced he has created stem cells from his own DNA — dubbed baby-Bryan — currently stored in a petri dish, with stated goals of testing experimental therapies, growing organs for transplantation, and generating young cells for injection, prompted by a recent autoimmune disease diagnosis. Scientists note that Johnson's language substantially overstates what stem cell reprogramming can currently achieve, and no peer-reviewed data accompanies the announcement. Spectacle or not, the story keeps pushing public conversation about the outer limits and ethics of personal longevity technology.
Read more →